Survey to Assess Why People Are Not Responding to Treatment in Hypertension
Observational Survey Assessing the Factors of Treatment Intensification in Uncontrolled Hypertensive Patients Under a Combination Therapy, Either Fixed or Not, of a Renin-Angiotensin System Blocker (RASB) and Hydrochlorothiazide (HCTZ), According to Their Level of Cardiovascular Risk.
3 other identifiers
observational
1,589
1 country
1
Brief Summary
This study will describe the factors influencing the physician in face of elevated blood pressure in already treated patients
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Nov 2009
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 1, 2009
CompletedStudy Start
First participant enrolled
November 1, 2009
CompletedFirst Posted
Study publicly available on registry
February 19, 2010
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2010
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2010
CompletedNovember 2, 2011
November 1, 2011
10 months
October 1, 2009
November 1, 2011
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Percentage of patients, according to the level of cardiovascular risk, who, at the end of the visit:- do not present any modification of hypertension treatment (therapeutic inertia) - present a change in the hypertension therapeutic
on day 1
Secondary Outcomes (1)
Analyses of the factors that had an impact on the therapeutic decision
on day 1
Study Arms (1)
Group 1
Interventions
Patients under daily life treatment receiving Pritor according to local drug information.
Eligibility Criteria
Uncontrolled hypertensive patients under a combination therapy, either fixed or not, of a renin-angiotensin system blocker and hydrochlorothiazide
You may qualify if:
- Men or women over 18
- Hypertensive patients
- Uncontrolled hypertension (blood pressure \>/=140/90 mmHg on the day of consultation or \>/=130/80 mmHg in diabetic patients or in patients suffering from kidney failure, or in elderly patients with a systolic blood pressure \>/=150 mmHg (in the absence of orthostatic hypotension)
- Patients treated with a combination, fixed or not, of Renin-Angiotensin System Blocker (RASB) + Hydrochlorothiazide (HCTZ)
- Patients examined in common medical care practice, whatever the reason for consultation
- Patients informed of the study
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Bayerlead
- International Clinical Trials Associationcollaborator
Study Sites (1)
Unknown Facility
Many Locations, France
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Bayer Study Director
Bayer
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
Study Record Dates
First Submitted
October 1, 2009
First Posted
February 19, 2010
Study Start
November 1, 2009
Primary Completion
September 1, 2010
Study Completion
September 1, 2010
Last Updated
November 2, 2011
Record last verified: 2011-11